Home > Clinical Trials > Cancer Clinical Trial > Brain and Nervous System > A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of (ERC1671/ GM-CSF / Cyclophosphamide) + Bevacizumab versus (Placebo Injection / Placebo pill) + Bevacizumab in the Treatment of Recurrent/Progressive, Bevacizumab Naïve Glioblastoma Multiforme and Gliosarcoma Patients (WHO Grade IV Malignant Gliomas)
Important information about COVID-19 ›

A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of (ERC1671/ GM-CSF / Cyclophosphamide) + Bevacizumab versus (Placebo Injection / Placebo pill) + Bevacizumab in the Treatment of Recurrent/Progressive, Bevacizumab Naïve Glioblastoma Multiforme and Gliosarcoma Patients (WHO Grade IV Malignant Gliomas)

UCI-13-14
NCT01903330
Cancer - Brain and Nervous System
Daniela Bota
Open
Treatment
Avastin, Bevacizumab, Cyclophosphamide, Cytoxan, ERC1671, GM-CSF, Placebo
Vaccine
II
Adult
Local

For information about cancer clinical trials at the UCI Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.